CARDIOTECH INTERNATIONAL, INC. TO ACQUIRE GISH BIOMEDICAL, INC.


FOR IMMEDIATE RELEASE

WOBURN, MASSACHUSETTS, AND RANCHO SANTA MARGARITA, CALIFORNIA, OCTOBER 28, 2002.
CardioTech  International  Inc.,  (AMEX:CTE)  and  Gish  Biomedical  Inc.,
(NASDAQ:GISH),  announced  the  execution  of  a  definitive  agreement allowing
CardioTech to acquire Gish Biomedical. At the effective time of the acquisition,
each  issued  and  outstanding  share  of  Gish  Biomedical common stock will be
converted  into  the  right to receive 1.3422 shares of CardioTech common stock.
Based on the number of shares of Gish Biomedical common stock outstanding, as of
the  date hereof, CardioTech expects to issue approximately 4,820,000 new shares
of  common  stock  in the transaction. The acquisition is subject to shareholder
approval  from  CardioTech  and  Gish  Biomedical  as  well  as  other  closing
conditions, and is expected to close in the first quarter of calendar year 2003.
The  transaction  will  be  structured  as  a  tax-free  reorganization.

This  acquisition  provides  CardioTech  with  a  leadership  presence  in  the
high-visibility  open-heart surgery field and advances its strategy of expanding
the  breadth  of  FDA-  cleared  products  it  provides to hospitals. CardioTech
recently  received  FDA clearance for an advanced wound dressing for which there
is  an  estimated  annual  $300  million  market.

Gish  Biomedical  is  located  in  Rancho  Santa  Margarita,  California,  and
specializes  in the manufacture and sale of products used in open-heart surgery,
vascular  access  and orthopedic surgery. Gish is registered as a medical device
manufacturer  with  the  FDA, the European Union and state agencies, such as the
California  Department  of  Health  Services  ("CDHS").

CardioTech International, Inc. maintains operations in Woburn, Massachusetts and
Plymouth,  Minnesota. CardioTech (i) is developing a polyurethane-based vascular
graft  (artificial  arteries)  for the treatment of heart disease, (ii) produces
medical  grade  polyurethanes  for  use  in  implantable  medical devices, wound
dressings,  and  (iii)  manufactures  medical  devices  on  an  OEM  basis.

Dr.  Michael  Szycher,  Chairman  and  CEO  of  CardioTech,  stated:  "The  Gish
acquisition  is  part  of  our  carefully  outlined  corporate  strategy  of
complementing  our  product  line in heart surgery. CardioTech will now have the
capability  of producing finished medical devices to create additional value and
increased  market  share.  We  are  particularly



gratified  that  the  entire  Gish  management and staff will remain in place to
maintain  continuity  for  current and future operations. This accomplished team
has  the  proven  ability to get products into production quickly. Following FDA
clearance, this team follows through by speeding products into manufacturing and
worldwide  sales.  "

Prior  to  the  merger  CardioTech and Gish Biomedical have 9,115,779 shares and
3,592,145  shares,  respectively,  outstanding.



The  Company believes that this release contains forward-looking statements that
are subject to risks and uncertainties. These forward-looking statements include
expected results. Such statements are based on management's current expectations
and  are  subject to a number of facts that could cause future results to differ
materially  from  the  forward-  looking  statements. As a result, the Company's
further  development involves a high degree of risk as detailed in the Company's
SEC  filings.

For  more  information  contact:

Michael  Szycher,  Ph.D.
Chief  Executive  Officer
(781)  933  4772

or

Dave  Gentry
Investor  Relations  Specialist
Aurelius  Consulting  Group
407-644-4256
success599@cs.com